Primary docetaxel chemotherapy in patients with breast cancer: Impact on response and survival

Breast Cancer Research and Treatment

Volumn 90, Issue 2, 2005, Pages 169-185

  Heys, Steven D ^a,b   Sarkar, Tarun ^a   Hutcheon, Andrew W ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Breast cancer; Docetaxel; Primary chemotherapy

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN; MITOXANTRONE; PACLITAXEL; TAMOXIFEN; THIOTEPA; VINCRISTINE; VINDESINE;

ANEMIA; ANOREXIA; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HOT FLUSH; HUMAN; INFECTION; LETHARGY; LEUKOPENIA; MASTECTOMY; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; STOMATITIS; SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; SURVIVAL RATE; TAXOIDS;

EID: 17644408035     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-004-1001-0     Document Type: Review

References (52)

1. AP Forrest PA Levack U Chetty RA Hawkins WR Miller JF Smyth TJ Anderson 1986 A human tumour model Lancet 2 840 842
2. L Mauriac M Durand A Avril JM Dilhuydy 1991 Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 2 347 354
3. SD Heys JM Eremin TK Sarkar AW Hutcheon A Ah-See O Eremin 1994 Role of multimodality therapy in the management of locally advanced carcinoma of the breast J Am Coll Surg 179 493 504
4. B Fisher J Bryant N Wolmark E Mamounas A Brown ER Fisher DL Wickerham M Begovic A DeCillis A Robidoux RG Margolese AB Cruz Jr JL Hoehn AW Lees NV Dimitrov HD Bear 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672 2685
5. IC Smith SD Heys AW Hutcheon ID Miller S Payne FJ Gilbert AK Ah-See O Eremin LG Walker TK Sarkar SP Eggleton KN Ogston 2002 Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel J Clin Oncol 20 1456 1466
6. KN Ogston ID Miller S Payne AW Hutcheon TK Sarkar I Smith A Schofield SD Heys 2003 A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival Breast 12 320 327
7. AW Hutcheon SD Heys TK Sarkar KN Ogston O Eremin LG Walker ID Miller 2003 Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial. Breast Cancer Res Treat 82 (Suppl 1) S9 Abstract 11
8. SD Heys AW Hutcheon TK Sarkar KN Ogston ID Miller S Payne I Smith LG Walker O Eremin 2002 Aberdeen Breast Group: Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial Clin Breast Cancer 3 (Suppl. 2) S69 S74
9. S Chan K Friedrichs D Noel T Pinter S Van Belle D Vorobiof R Duarte M Gil Gil I Bodrogi E Murray L Yelle G von Minckwitz S Korec P Simmonds F Buzzi R Gonzalez Mancha G Richardson E Walpole M Ronzoni M Murawsky M Alakl A Riva 1999 Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer J Clin Oncol 17 2341 2354
10. JM Nabholtz C Falkson D Campos J Szanto M Martin S Chan T Pienkowski J Zaluski T Pinter M Krzakowski D Vorobiof R Leonard I Kennedy N Azli M Murawsky A Riva P Pouillart 2003 TAX 306 Study Group: docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial J Clin Oncol 21 968 975
11. PM Ravdin HA 3 rd Burris G Cook P Eisenberg M Kane WA Bierman J Mortimer E Genevois RE Bellet 1995 Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer J Clin Oncol 13 2879 2885
12. A Makris TJ Powles SE Ashley J Chang T Hickish VA Tidy AG Nash HT Ford 1998 A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer Ann Oncol 9 1179 1184
13. L Mauriac G MacGrogan A Avril M Durand A Floquet M Debled JM Dilhuydy F Bonichon 1999 Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10 47 52
14. SM Scholl A Fourquet B Asselain JY Pierga JR Vilcoq JC Durand T Dorval T Palangie M Jouve P Beuzeboc P Pouillart 1994 Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A 645 652
15. VF Semiglazov EE Topuzov JL Bavli VM Moiseyenko OA Ivanova IK Seleznev AA Orlov NY Barash OM Golubeva OF Chepic 1994 Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer Ann Oncol 5 591 595
16. SM Scholl JY Pierga B Asselain P Beuzeboc T Dorval E Garcia-Giralt M Jouve T Palangie Y Remvikos JC Durand A Fourquet P Pouillart 1995 Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31A 1969 1975
17. N Wolmark J Wang E Mamounas J Bryant B Fisher 2001 Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 J Natl Cancer Inst Monogr 30 96 102
18. P Chollet S Amat H Cure M de Latour G Le Bouedec MA Mouret-Reynier JP Ferriere JL Achard J Dauplat F Penault-Llorca 2002 Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer Br J Cancer 86 1041 1046
19. 18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer J Clin Oncol 18 1689 1695
20. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy J Clin Oncol 18 1676 1688
21. IC Smith ID Miller 2001 Issues involved in research into the neoadjuvant treatment of breast cancer Anticancer Drugs 12 (Suppl. 1) S25 S29
22. J Chang TJ Powles DC Allred SE Ashley GM Clark A Makris L Assersohn RK Gregory CK Osborne M Dowsett 1999 Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer J Clin Oncol 17 3058 3063
23. J Sjostrom C Blomqvist P Heikkila KV Boguslawski A Raisanen-Sokolowski NO Bengtsson I Mjaaland P Malmstrom B Ostenstadt J Bergh E Wist V Valvere E Saksela 2000 Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer Clin Cancer Res 6 3103 3110
24. PA Ellis IE Smith K McCarthy S Detre J Salter M Dowsett 1997 Preoperative chemotherapy induces apoptosis in early breast cancer Lancet 349 849 letter
25. B Fisher N Wolmark ER Fisher M Deutsch 1985 Lumpectomy and axillary dissection for breast cancer: surgical, pathological, and radiation considerations World J Surg 9 692 698
26. MC Bissery D Guenard F Gueritte-Voegelstein F Lavelle 1991 Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a Taxol analogue Cancer Res 51 4845 4852
27. J Crown J M O'Leary 2000 The taxanes: an update Lancet 355 1176 1178
28. AP Launchbury N Habboubi 1993 Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity Cancer Treat Rev 19 197 228
29. ® does not change the pharmacokinetic (PK) profile of doxorubicin (Dox) or doxorubicinol (Dx-ol) Proc Am Soc Clin Oncol 17 221a (Abstract 853)
30. S Amat P Bougnoux F Penault-Llorca F Fetissof H Cure F Kwiatkowski JL Achard G Body J Dauplat P Chollet 2003 Primary docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate Br J Cancer 88 1339 1345
31. ®) in unfavourable locally advanced breast cancer (LABC) Eur J Cancer 37 6 (Abstract 622)
32. ®) is effective as primary chemotherapy for stage II and III breast cancer. Results of a phase II, multicenter study. Clin Cancer Res 9 686 692
33. WJ Gradishar 1997 Docetaxel as primary chemotherapy in patients with stage III breast cancer Oncology 11 (Suppl. 8) 15 18
34. B Chevallier H Roche JP Olivier P Chollet P Hurteloup 1993 Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16 223 228
35. DM Sataloff BA Mason AJ Prestipino UL Seinige CP Lieber Z Baloch 1995 Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome J Am Coll Surg 180 297 306
36. G Ganem M Tubiana-Hulin P Fumoleau M Combe JL Misset JM Vannetzel T Bachelot LR De Ybarlucea V Lotz B Bendahmane V Dieras 2003 Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer Ann Oncol 14 1623 1628
37. V Valero FJ Esteva AA Sahin DJ Booser EA Strom LT Esparza-Guerra MI Ross MF Rosales NK Ibrahim M Cirstofanil TA Buchholz KK Hunt GN Hortobagyi 2000 Phase II trial of primary chemotherapy with docetaxel and doxorubicin, surgery, adjuvant CMF, and radiotherapy +/- tamoxifen in locally advanced breast cancer Breast Cancer Res Treat 64 69 (Abstract 253)
38. G von Minckwitz SD Costa W Eiermann JU Blohmer AH Tulusan C Jackisch M Kaufmann 1999 Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel J Clin Oncol 17 1999 2005
39. G von Minckwitz SD Costa G Raab JU Blohmer H Eidtmann J Hilfrich E Merkle C Jackisch G Gademann AH Tulusan W Eiermann E Graf M Kaufmann 2001 German Preoperative Adriamycin-Docetaxel and German Adjuvant Breast Cancer Study Groups: Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study J Clin Oncol 19 3506 3515
40. C Ferlini G Scambia M Distefano P Filippini G Isola A Riva E Bombardelli A Fattorossi P Benedetti Panici S Mancuso 1997 Synergistic antiproliferative activity of tamoxifen and docetaxel on three estrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis Br J Cancer 75 884 891
41. A de Matteis F Nuzzo G D'Aiuto V Labonia G Landi E Rossi AA Mastro G Botti E De Maio F Perrone 2002 Docetaxel plus epidoxorubicin as primary treatment in patients with large operable or locally advanced carcinoma of the breast. A single-center, phase II study. Cancer 94 895 901
42. C Wenzel GJ Locker M Schmidinger M Rudas S Taucher MF Gnant R Jakesz GG Steger 2002 Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel + granulocyte colony stimulating factor Anticancer Drugs 13 67 74
43. L Luporsi L Vanlemmens B Coudert F Mayer J Bonneterre T Petit C Borel M Hirsch P Bey 2000 6 cycles of FEC 100 versus 6 cycles of epirubicin-docetaxel (ED) as neoadjuvant chemotherapy in operable breast cancer patients (Pts): preliminary results of a randomized phase II trial of Girec S01 Proc Am Soc Clin Oncol 19 92 (Abstract 355)
44. A Milla S Morales MA Burillo P Borrega I Machenes T Checa J Janariz JJ Illaramendi J Lizon 2001 High-dose epirubicin plus docetaxel in locally advanced breast cancer (LABC). An ONCOPAZ and associated hospitals study. Breast Cancer Res Treat 69 271 (Abstract 359)
45. C Wenzel GJ Locker U Pluschnig CC Zielinski M Rudas G Oberhuber MF Gnant S Taucher R Jakesz GG Steger 2002 Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer Cancer Chemother Pharmacol 50 155 159
46. KD Miller W McCaskill-Stevens J Sisk DM Loesch F Monaco R Seshadri GW Sledge Jr 1999 Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group J Clin Oncol 17 3033 3037
47. G von Minckwitz G Raab M Schuette J Hilfrich JU Blohmer B Gerber SD Costa E Merkle H Eidtmann W Lampe C Jackisch A duBois A Caputo M Kaufmann Jr 2002 Dose-dense versus sequential adriamycin/docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2-3, N0-2, M0)-primary endpoint analysis of the GEPAR-DUO Study Proc Am Soc Clin Oncol 21 43a (Abstract 168)
48. HD Bear S Anderson A Brown R Smith EP Mamounas B Fisher R Margolese H Theoret A Soran DL Wickerham N Wolmark 2003 National Surgical Adjuvant Breast and Bowel Project Protocol B-27: the effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-27 J Clin Oncol 21 4165 4174
49. C Jackisch G von Minckwitz H Eidtmann SD Costa G Raab JU Blohmer M Schutte B Gerber E Merkle G Gademann D Lampe J Hilfrich AH Tulusan A Caputo M Kaufmann 2002 Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis Clin Breast Cancer 3 276 280
50. AW Hutcheon KN Ogston SD Heys IC Smith T Whitaker ID Miller S Payne A Ah-See O Eremin P Eggleton 2000 The Aberdeen Breast Group: primary chemotherapy in the treatment of breast cancer: significantly enhanced clinical and pathological response with docetaxel Proc Am Soc Clin Oncol 19 83a (Abstract 317)
51. J Hurley P Doliny C Gomez L Raez J Boggs S Franco Y Lee 2000 High complete pathologic response rate of locally advanced breast cancers (LABC) to neoadjuvant (NEO) docetaxel and cisplatin chemotherapy Proc Am Soc Clin Oncol 19 127 (Abstract 494)
52. JE Hurley P Doliny P Velez U Guatam I Reis O Silva C Gomez-Fernandez Y Lee SX Franco 2001 High rate of axillary node clearance with neoadjuvant Herceptin, Taxotere, and cisplatin in locally advanced and inflammatory breast cancer Breast Cancer Res Treat 69 300 (Abstract 516)